1,199 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Wallace Advisory Group LLC

Wallace Advisory Group LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,199 shares of the company’s stock, valued at approximately $766,000.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of IDEXX Laboratories by 2.3% during the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after purchasing an additional 54,402 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of IDEXX Laboratories by 156.2% in the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after buying an additional 884,808 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of IDEXX Laboratories by 37.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock valued at $452,046,000 after buying an additional 290,551 shares during the period. William Blair Investment Management LLC grew its position in IDEXX Laboratories by 7.5% during the second quarter. William Blair Investment Management LLC now owns 685,088 shares of the company’s stock worth $367,440,000 after buying an additional 47,977 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in IDEXX Laboratories by 1.8% during the 2nd quarter. Legal & General Group Plc now owns 648,626 shares of the company’s stock worth $347,884,000 after acquiring an additional 11,768 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 0.8%

Shares of NASDAQ IDXX opened at $687.94 on Friday. The company has a market cap of $54.93 billion, a price-to-earnings ratio of 54.56, a PEG ratio of 4.11 and a beta of 1.67. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock has a 50-day moving average price of $694.64 and a two-hundred day moving average price of $630.17.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. UBS Group boosted their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Barclays started coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective for the company. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Finally, BTIG Research boosted their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.